Ostarine will be the closest SARM to staying authorized in medication and is also at this time in section II scientific trials. Like SARMs in general, MK-2866 targets androgen receptors on a selective basis and avoids creating the varieties of destructive side effects associated with substances like testosterone, human growth https://mauricey780xxu2.webbuzzfeed.com/profile